logo-loader
viewActinium Pharmaceuticals Inc

Actinium Pharmaceuticals is misunderstood, says Oppenheimer

The company is undervalued and has catalysts coming up in the next year

Cancer cells
Actinium Pharmaceuticals is a clinical stage biopharmaceutical company fighting cancer.

Analysts at Oppenheimer said on Thursday that shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) are significantly undervalued and should be rated as Outperform with a US$5 price target because of catalysts in the next 12 to 18 months.

After attending a conference call Thursday, Oppenheimer said Actinium is approaching an inflection point on its outlook for a Phase 3 Sierra study of Iomab-B for bone marrow transplant patients. The drug also has clinical trial support from the foremost bone marrow transplant centers in the US. 

"We believe that investors are little aware of the furious pace at which ATNM is updating the Iomab-B Phase 3 clinical trial, adding more Actimab-A indications and thoughtfully building out the management team," Oppenheimer analysts wrote in a research note. "We advise investors to carefully consider a misunderstood name."

READ: Actinium Pharmaceuticals unveils new clinical trial for leukemia with its treatment Actimab-A

Oppenheimer assigned the value of Iomab-B at US$2.60/share, applying a 6x mulitple to estimated 2025 sales of US$323mln. Along with other programs, the research analyst believes a target price of US$5 is justified.

The key downside risks to the rating, Oppenheimer wrote, is the failure of the Iomab-B study and another Phase 2 study for another drug to fight cancer. 

Actinium Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options.

Shares were down 1.3% to US$0.61 on Thursday.

Quick facts: Actinium Pharmaceuticals Inc

Price: 0.2465 USD

NYSE:ATNM
Market: NYSE
Market Cap: $40.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Alkane Resources hits almost 700 metres of mineralisation in...

Alkane Resources Ltd (ASX:ALK) managing director Nic Earner updates Proactive on follow-up drill results from the Boda prospect within the wider Northern Molong Porphyry Project (NMPP) near Orange in New South Wales. The drilling is part of a 5,000-metre diamond core drilling exploration...

15 hours, 57 minutes ago

2 min read